Featured Research

from universities, journals, and other organizations

Most Charnley total hip replacements viable after 35 years

Date:
March 14, 2014
Source:
American Academy of Orthopaedic Surgeons
Summary:
In a new study, researchers sought to evaluate the clinical, radiographic and functional outcomes of a Charnley total hip replacement -- a traditional hip prosthesis consisting of a polyethylene acetabular (plastic) cup and a metal femoral head -- in patients under age 50 at a minimum of 35 years after the initial surgery.

In the new study, "Assessment of Durability and Function at Minimum 35-Year Follow up of THR Patients 50 and Under," researchers sought to evaluate the clinical, radiographic and functional outcomes of a Charnley total hip replacement(THR), a traditional hip prosthesis consisting of a polyethylene acetabular (plastic) cup and a metal femoral head, in patients under age 50 at a minimum of 35 years after the initial surgery.

Out of 69 THR patients (93 hip replacements) who participated in a 25-year follow up assessment, 32 were still alive (44 percent) and 30 were available for an evaluation. Out of the original 93 hip replacements, 28 required revision surgery. The 30 patients with viable hip components were assessed through quality of life and hip scores, and activity measurements, including six-minute walk and pedometer monitoring.

Although 63.5 percent of the original hip replacements were functioning at the latest follow-up examination or at the time of patient death, a significant decrease in activity level, as measured by functional scores, was seen over time. Age and health related factors, as opposed to implant failure, limited activity in this cohort at long-term follow up.

According to the study authors, the results reflect the durability of cemented hip replacements, and provide a benchmark comparison for THR performed in younger patients with other designs, materials and techniques.


Story Source:

The above story is based on materials provided by American Academy of Orthopaedic Surgeons. Note: Materials may be edited for content and length.


Cite This Page:

American Academy of Orthopaedic Surgeons. "Most Charnley total hip replacements viable after 35 years." ScienceDaily. ScienceDaily, 14 March 2014. <www.sciencedaily.com/releases/2014/03/140314093739.htm>.
American Academy of Orthopaedic Surgeons. (2014, March 14). Most Charnley total hip replacements viable after 35 years. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2014/03/140314093739.htm
American Academy of Orthopaedic Surgeons. "Most Charnley total hip replacements viable after 35 years." ScienceDaily. www.sciencedaily.com/releases/2014/03/140314093739.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins